159382-23-7

Basic information

• Product Name: 4,6-QuinazolinediaMine
• Synonyms: 4,6-DiaMinoquinazoline;4,6-QuinazolinediaMine
• CAS NO: 159382-23-7
• Molecular Formula: C₈H₈N₄
• Molecular Weight: 160.17592
• Product Categories: Amines, Aromatics, Heterocycles, Intermediates, Metabolites & Impurities
• Mol File: 159382-23-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,6-QuinazolinediaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-QuinazolinediaMine(159382-23-7)
• EPA Substance Registry System: 4,6-QuinazolinediaMine(159382-23-7)

Safety Data

• Hazardous Substances Data: 159382-23-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,6-Quinazolinediamine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its presence as a predicted metabolite of A621350 suggests that it may play a role in the metabolism and activity of related drugs.
Used in NOP Antagonist Development:
4,6-Quinazolinediamine is used as a key component in the preparation of potential nociceptin receptor (NOP) antagonists. NOP antagonists are of interest in the pharmaceutical industry due to their potential therapeutic applications in treating pain, addiction, and other conditions related to the NOP receptor.

Upstream product

• 49675-68-5 4-amino-6-nitroquinazoline 
• 49675-68-5 6-nitroquinazoline-4-(3H)-imine 
• 17420-30-3 5-nitroanthranilonitrile 
• 874497-57-1 N-(6-nitroquinazolin-4-yl)acetamide 
• 19815-16-8 4-chloro-6-nitro-quinazoline 

Downstream Products

• 372982-62-2 phenylmethyl (2S)-2-{[(4-amino-6-quinazolinyl)amino]carbonyl}-1-pyrrolidinecarboxylate 
• 159382-29-3 2-desamino-5,8-dideazaisoaminopterin 
• 170032-06-1 2-desamino-5,8-dideazaisoaminopterin di-tert-butyl ester 

Relevant articles and documents

Design and synthesis of novel quinazoline derivatives and their evaluation as PI3Ks inhibitors

The aim of this work was to synthesize 4-acetamido-, 4-amino- and 4-oxo-6-substituted aminoquinazolines and to evaluate them as phosphoinositide 3-kinases (PI3Ks) inhibitors. The respective chemotype was designed based on combining the structural features

Studies on the Antitumor Effects of Analogues of 5,8-Dideazaisofolic Acid and 5,8-Dideazaisoaminopterin

Six new analogues of 5,8-dideazaisofolic acid and 5,8-dideazaisoaminopterin were synthesized in an effort to obtain enhanced antitumor activity. The modifications included the replacement of the 2-amino group by hydrogen or methyl as well as the inclusion of a methyl substituent at position 9. Based upon activity against L1210 leukemia cells in culture, three of the new analogues together with one compound described previously were evaluated for cytotoxicity in vitro using three human tumor cell lines (Colo 320 DM, Hep G2 and HL-60). The most effective compound was 2-desamino-N9-methyl-5,8-dideazaisoaminopterin (2c) with the HL-60 cells being the most sensitive to its cytotoxic effects. These analogues were evaluated in vitro as inhibitors of dihydrofolate reductase (DHFR) and thymidylate synthase (TS) from human as well as bacterial (Lactobacillus casei) sources. All four of the 4-amino analogues were most effective toward L. casei DHFR compared with human DHFR, with 2-desamino-2-methyl-5,8-dideazaisoaminopterin (2d) and its 9-methyl derivative (2e) having 818- and 430-fold greater selectivity (L. casei/human). Most of the compounds studied were found to be only modest inhibitors of human TS (I50 values = 1.5 to 20 μM) and were therefore at least 40-fold less inhibitory than 10-propargyl-5,8-dideazafolic acid. Nevertheless, reversal of cytotoxicity studies with thymidine, hypoxanthine and folinic acid using the HL-60 cell line suggested that TS is the primary target for these analogues.